{"id":386751,"date":"2020-11-23T08:33:34","date_gmt":"2020-11-23T13:33:34","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386751"},"modified":"2020-11-23T08:33:34","modified_gmt":"2020-11-23T13:33:34","slug":"cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/","title":{"rendered":"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SAN DIEGO<\/span>, Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; <b>Cardiff Oncology, Inc. (Nasdaq:\u00a0CRDF)<\/b>, a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will be participating in the upcoming Piper Sandler 32<sup>nd<\/sup> Annual Virtual Healthcare Conference. Beginning today, <span class=\"xn-chron\">November 23<\/span><sup>rd<\/sup>, a pre-recorded fireside chat with company management will be available for viewing anytime through <span class=\"xn-chron\">December 3<\/span><sup>rd <\/sup>by accessing the recording library on the <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990109-1&amp;h=2246309086&amp;u=https%3A%2F%2Fpipersandler.zoom.us%2Frec%2Fplay%2FyWsToLg3qEPn-QMPX-UOI6lgKvKS3qq5ydC_XMAZFa-0kKbZCDwhF2OifBZaZ1rXOyYoiyLIwDP3c5Wd._OmdGf_gRxi-Qo5t&amp;a=Piper+Sandler\" rel=\"nofollow noopener noreferrer\">Piper Sandler<\/a>\u00a0conference site. <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg\" title=\"Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Our investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. We are assessing tumor genomics and using our expertise in biomarker technology to rapidly evaluate patient response to treatment. (PRNewsfoto\/Cardiff Oncology, Inc.)\" alt=\"Cardiff Oncology is a clinical-stage biotechnology company and our mission is to develop new treatment options for cancer patients in indications with the greatest medical need. Our goal is to overcome resistance, improve response to treatment and increase overall survival. Our investigational drug, onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, is being evaluated in combination with standard-of-care chemotherapy and targeted therapeutics. We are assessing tumor genomics and using our expertise in biomarker technology to rapidly evaluate patient response to treatment. (PRNewsfoto\/Cardiff Oncology, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Cardiff Oncology will also be participating in 1&#215;1 meetings from <span class=\"xn-chron\">December 1<\/span><sup>st<\/sup> \u2013 3<sup>rd<\/sup>. \u00a0Meetings can be requested exclusively via Piper Sandler. <\/p>\n<p>\n        <b>About Cardiff Oncology, Inc.<br \/><\/b>Cardiff Oncology (formerly Trovagene, Inc.) is a clinical-stage biotechnology company with the singular mission of developing new treatment options for cancer patients in indications with the greatest medical need.\u00a0 Our goal is to overcome resistance, improve response to treatment and increase overall survival.\u00a0 We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.\u00a0 Our clinical development programs incorporate tumor genomics and biomarker technology to enable assessment of patient response to treatment. We have three ongoing clinical programs that are demonstrating the safety and efficacy of onvansertib: a Phase\u00a01b\/2 study of onvansertib in combination with FOLFIRI\/Avastin\u00ae in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 study of onvansertib in combination with Zytiga\u00ae (abiraterone)\/prednisone in metastatic castration-resistant prostate cancer (mCRPC); and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia (AML). For more information, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=2990109-1&amp;h=364706896&amp;u=https%3A%2F%2Fcardiffoncology.com%2F&amp;a=https%3A%2F%2Fcardiffoncology.com\" rel=\"nofollow noopener noreferrer\">https:\/\/cardiffoncology.com<\/a>.\u00a0\u00a0<\/p>\n<p>\n        <b><br \/>\n          <u>Cardiff Oncology Contact:<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span class=\"xn-person\">Vicki Kelemen<\/span><br \/>\n        <br \/>EVP and Chief Operating Officer<br \/>858-952-7652<br \/><a target=\"_blank\" href=\"mailto:vkelemen@cardiffoncology.com\" rel=\"nofollow noopener noreferrer\">vkelemen@cardiffoncology.com<\/a>\u00a0\u00a0<\/p>\n<p>\n        <b><br \/>\n          <u>Investor Contact:<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span class=\"xn-person\">Joyce Allaire<\/span><br \/>\n        <br \/>LifeSci Advisors<br \/>212-915-2569<br \/><a target=\"_blank\" href=\"mailto:jallaire@lifesciadvisors.com\" rel=\"nofollow noopener noreferrer\">jallaire@lifesciadvisors.com<\/a>\u00a0<\/p>\n<p>\n        <b><br \/>\n          <u>Media Contact:<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span class=\"xn-person\">Karen O&#8217;Shea<\/span>, Ph.D.<br \/>LifeSci Communications<br \/>929-469-3860<br \/><a target=\"_blank\" href=\"mailto:koshea@lifescicomms.com\" rel=\"nofollow noopener noreferrer\">koshea@lifescicomms.com<\/a>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA00273&amp;sd=2020-11-23\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference-301178519.html\">http:\/\/www.prnewswire.com\/news-releases\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference-301178519.html<\/a><\/p>\n<p>SOURCE  Cardiff Oncology, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA00273&amp;Transmission_Id=202011230830PR_NEWS_USPR_____LA00273&amp;DateId=20201123\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SAN DIEGO, Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; Cardiff Oncology, Inc. (Nasdaq:\u00a0CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler\u00a0conference site. Cardiff Oncology will also be participating in 1&#215;1 meetings from December 1st \u2013 3rd. \u00a0Meetings can be requested exclusively via Piper Sandler. About Cardiff Oncology, Inc.Cardiff Oncology (formerly Trovagene, Inc.) is a &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386751","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SAN DIEGO, Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; Cardiff Oncology, Inc. (Nasdaq:\u00a0CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler\u00a0conference site. Cardiff Oncology will also be participating in 1&#215;1 meetings from December 1st \u2013 3rd. \u00a0Meetings can be requested exclusively via Piper Sandler. About Cardiff Oncology, Inc.Cardiff Oncology (formerly Trovagene, Inc.) is a &hellip; Continue reading &quot;Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T13:33:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference\",\"datePublished\":\"2020-11-23T13:33:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/\"},\"wordCount\":341,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/\",\"name\":\"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"datePublished\":\"2020-11-23T13:33:34+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1165624\\\/Cardiff_Oncology_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference - Market Newsdesk","og_description":"PR Newswire SAN DIEGO, Nov.\u00a023, 2020 \/PRNewswire\/ &#8212; Cardiff Oncology, Inc. (Nasdaq:\u00a0CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler\u00a0conference site. Cardiff Oncology will also be participating in 1&#215;1 meetings from December 1st \u2013 3rd. \u00a0Meetings can be requested exclusively via Piper Sandler. About Cardiff Oncology, Inc.Cardiff Oncology (formerly Trovagene, Inc.) is a &hellip; Continue reading \"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T13:33:34+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference","datePublished":"2020-11-23T13:33:34+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/"},"wordCount":341,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/","name":"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","datePublished":"2020-11-23T13:33:34+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1165624\/Cardiff_Oncology_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cardiff-oncology-to-participate-in-fireside-chat-at-the-piper-sandler-32nd-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386751"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386751\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}